- Company
- Daewoong is accelerating its global expansion
- by Kim, Jin-Gu May 4, 2023 05:50am
- Daewoong Pharmaceutical Group is speeding up CAPA expansion. In order to speed up its global expansion, it decided to invest 250 billion won in establishing two new factories this year alone. Daewoong Pharmaceutical plans to expand its botulinum toxin production capacity to 3.6 times the previous level by constructing a third plant for Nabota
- Company
- Rare diseases still left neglected in Korea’s healthcare
- by Eo, Yun-Ho May 4, 2023 05:49am
- Patients with rare diseases suffer due to the rarity of their disease. Even when treatments are available, the drugs have difficulty receiving reimbursement as it is difficult to prove cost-effectiveness and predict financial expenditures for the drugs due to the small number of patients. The government is well aware of such difficulties. Thi
- Opinion
- [Reporter's View] Patent expired original
- by Lee, Tak-Sun May 3, 2023 05:38am
- For original drug patents that have expired, the upper limit is adjusted under the authority of the Ministry of Health and Welfare when a generic drug with the same product appears. Original drugs will be reduced to 70% of the previous price for one year, and from the second year onwards, the price will drop to the same 53.55% level as gener
- Company
- Will Verzenio succeed in expanding benefits
- by Eo, Yun-Ho May 3, 2023 05:38am
- Attention is focusing on whether Verzenio will succeed in expanding early breast cancer insurance benefits. According to the related industry, the agenda to expand reimbursement for early breast cancer with a high recurrence risk of Verzenio, a breast cancer treatment with CDK4/6 inhibitory mechanism of Lilly Korea, is expected to be presente
- Policy
- The expansion of MPOX vaccination
- by Lee, Jeong-Hwan May 3, 2023 05:38am
- 17 million adult males aged 20 to 64, 170,000, about 1%, the high-risk group estimated As the number of MPOX cumulative confirmed cases in Korea increased to 49, concerns about community infection grew, and domestic quarantine authorities decided to expand the target of third-generation MPOX vaccine to 'high-risk subjects of infection', draw
- Company
- Boryung fails 3 of 5 patent challenges
- by Kim, Jin-Gu May 3, 2023 05:38am
- Boryung's omnidirectional patent challenge strategy on orignial anticancer drugs has been making slow progress. Since the end of 2021, Boryung filed patent challenges on 5 anticancer drugs, and lost or voluntarily withdrew 3 of those claims. Despite the strong drive it has been making for its anticancer drug business with plans to launch gene
- Company
- ‘Korea’s low reimb of orphan drugs needs to be improved’
- by Eo, Yun-Ho May 3, 2023 05:38am
- Study results have shown that Korea has low access to rare disease treatments. The Korean Research-based Pharmaceutical Industry Association (KRPIA) recently announced study results that stress Korea’s need to improve its reimbursement system in consideration of the characteristics held by rare diseases and rare disease treatments base
- Policy
- Pemazyre received domestic product approval
- by Lee, Hye-Kyung May 2, 2023 03:40pm
- Handok's locally advanced or metastatic cholangiocarcinoma treatment Pemazyre received domestic product approval on the 25th. The Ministry of Food and Drug Safety (Minister Oh Yoo-kyung) announced that it had approved three doses (4.5mg, 9mg, 13.5mg) of Pemazyre, an orphan drug. Pemazyre is an oral FGFR inhibitor that inhibits the proliferati
- Company
- Boryung signed a contract to establish a joint venture with
- by Kim, Jin-Gu May 2, 2023 05:36am
- Boryung announced on the 26th that it signed a contract to establish a joint venture (JV) with Axiom Space of the United States on the 25th (local time) to jointly promote the space business. Boryung CEO Kim Jeong-kyun, who visited the United States on an economic mission to the United States, signed a JV establishment contract with Axiom Spa
- Company
- Eylea Prefilled Syringe can be prescribed at GHs in KOR
- by Eo, Yun-Ho May 2, 2023 05:36am
- The pre-filled syringe formulation of Eylea can now be prescribed at general hospitals in Korea. According to industry sources, Bayer Korea's Wet Age-Related Macular Degeneration (wAMD) treatment 'Eylea Pre-filled Syringe,’ which was released with insurance reimbursement in October last year, has passed the drug committee reviews of tert
